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Abstract
Inhibition of p-glycoprotein under hyperglycemic conditions has been reported in various barrier tissues including blood-
brain barrier, intestine, and kidney, and has been linked to significant clinical complications. However, whether this is also
true for the outer blood-retinal barrier constituted by retinal pigment epithelium, or has a role in pathogenesis of diabetic
retinopathy is not yet clear. In this study, using cultured human retinal pigment epithelium cell line D407, we found that
high glucose exposure induced a significant decrease in p-glycoprotein expression both at mRNA and at protein levels,
accompanied by an attenuated p-glycoprotein activity determined by intracellular rhodamine 123 retention. In marked
contrast, the expressions of both mRNA and protein levels of inducible nitrate oxide synthase (iNOS) increased, and were
accompanied by increased extracellular nitrate/nitrite production by Griess reaction. In addition, mRNA levels of nuclear
receptors revealed a decreased expression of pregnane X receptor after the exposure of high glucose. However, the
subsequent alterations in production of nitrate/nitrite, functional expression of p-glycoprotein, and mRNA levels of
pregnane X receptor were partially blocked when pretreated with S,S9-1,3-phenylene-bis(1,2-ethanediyl)-bis-isothiour-
eaN2HBr (PBITU), a selective iNOS inhibitor. Moreover, the effects of PBITU were antagonized with the addition of L-arginine,
a substrate for NO synthesis. Our in vitro results suggest for the first time that iNOS induction plays a novel role in decreased
p-glycoprotein expression and transport function at the human outer blood-retinal barrier under hyperglycemic conditions
and further support the concept of inhibiting iNOS pathway as a therapeutic strategy for diabetic retinopathy.
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Introduction
The retinal pigment epithelium (RPE) is a monolayer of
pigmented cells located between the neural retina and the choroid,
and therefore constitutes the outer blood-retinal barrier (BRB, for
a review see ref. 3). The inner BRB is mainly constituted by
endothelial cells. Because the RPE forms the outer BRB and is
essential for removal of waste products and entry of nutrients into
the retina, any disturbance in normal transport function of these
cells necessarily has detrimental consequences for the retina. It is
well documented that defects in RPE function may underlie a
number of sight-threatening conditions, such as age-related
macular degeneration, proliferative vitreoretinopathy, and diabet-
ic retinopathy (DR) [1,2,3].
Diabetic retinopathy is the most serious complication of diabetic
eye disease and one of the most common leading causes of
irreversible blindness worldwide [4,5]. The role of hyperglycemia
in the development of DR has now been strongly affirmed.
Breakdown of the retinal barrier function is considered to be the
basis of the pathogenesis of DR [3,6]. Numerous studies on
pathogenesis of DR have been focused on the impairment of the
neural retina and the inner BRB [4,7]. It is increasingly recognized
that impairment of the outer BRB plays an important role in the
initiation and progress of early DR [3,8]. We thus suspected that
the abnormal elevated blood glucose levels during the develop-
ment of DR may potentially disturb the barrier function at the
outer BRB. Indeed, Liu and colleague [9] have reported that the
alterations in expression of efflux pumps such as p-glycoprotein (P-
gp) could lead to damages in barrier integrity in diabetes and could
be restored by insulin therapy. However, the direct data for the
effects of high glucose or hyperglycemia on the transport functions
at the outer BRB are not yet available.
As a best-characterized efflux transport protein, P-gp is
considered by far the most important among efflux transporters
expressed in mammalian tissues [10]. P-gp is a membrane
phosphoglycoprotein encoded by the multidrug resistance
MDR1 gene which has ATP-dependent drug efflux pump function
[10]. Besides the overexpression of P-gp in multidrug-resistant cell
lines, it is mainly expressed in cells with active secretory and
excretory functions, such as renal proximal tubule, intestinal
epithelium and blood-brain barrier [10,11,12,13], which indicates
the primary role of P-gp in secretion and transport. Recently, basal
P-gp functional expression was also detected in the human RPE
cells [14,15]. Attenuated P-gp expression and functions by high
glucose have been reported in various tissues, such as blood-brain
barrier [16,17], intestine [11], liver [18,19], and kidney [19,20],
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whether this is also true for the outer BRB or has a role in
pathogenesis of DR is still mysterious. In the present study, we
show that inducible nitrate oxide synthase (iNOS) signaling
pathway is induced in the cultured human RPE cells by the
exposure of high glucose, and high glucose-induced iNOS
pathway results in the inhibition of functional expression of P-gp
and transcriptional expression of pregnane X receptor (PXR), a
nuclear receptor that regulates expression of drug metabolizing
enzymes and efflux transporters [13,21]. We propose that iNOS
induction by high glucose suppress the transcription of PXR, and
thereby inhibit the expression and activity of P-gp at the human
outer BRB.
Materials and Methods
Cell Culture
The human RPE cell line D407 was generously given by
Richard Hunt (Department of Immunology and Pathology,
University of South Carolina Medical School, Columbia, SC,
USA). These cells were shown to possess most metabolic and
morphologic characteristics of RPE cells in vivo [22] and express
functional P-gp [23]. The D407 cells were incubated in DMEM
with normal (5.5 mM), intermediate (12.5 mM) or high (25 and
50 mM) glucose, supplemented with 10% (vol/vol) fetal bovine
serum (Gibco BRL, Grand Island, NY, USA), 100 U/mL
penicillin, and 100 mg/mL streptomycin. Cells were maintained
in humidified atmosphere of 5% CO2 at 37uC. The culture
medium was replaced with fresh medium every 2 to 3 days.
Cell proliferation
Cell proliferation was determined by the Thiazolyl blue
tetrazolium bromide (MTT) assay. D407 cells were seeded at a
density of ten thousand per well in a 96-well plate and incubated
with various concentrations of glucose at 37uC under 5% CO2 for
6 h–14 d. MTT was added into the media at the final
concentration of 0.5 mg/ml for 4 h to allow MTT to be
metabolized. After media were dumped off, cells were resuspended
in formazan (MTT metabolic product) in 200 ml dimethyl
sulfoxide (DMSO). Optical density was read at 540 nm and
background was subtracted at 670 nm.
Indirect determination of nitric oxide production
Nitric oxide (NO) production was determined by measuring
extracellular nitrate/nitrite concentrations in culture supernatants.
After pretreatment with different concentrations of S,S9-1,3-
phenylene-bis(1,2-ethanediyl)-bis-isothioureaN2HBr (PBITU, 0.2,
0.4, and 0.8 mM, Santa Cruz Biotechnology, CA, USA), the cells
were cultured in hyperglycemic conditions for 0, 6, 12, 24 and
48 h, and NO production was assessed with Griess reaction. Cell
supernatants (1 000 mL) were mixed with 1 000 mL of the Griess
reagent, a mixture (1:1) of 0.2% naphthylethylene-diamine and
2% sulfonamide in 5% phosphoric acid. After 10-min incubation
at room temperature, the absorbency was read at 540 nm on a
spectrophotometer. The nitrate/nitrite levels were extrapolated
from NaNO2 calibration curve.
Quantitative real-time polymerase chain reaction (Q-PCR)
After pretreatment with different concentrations of PBITU ( 0.2,
0.4, and 0.8 mM) in the presence or absence of 1.0 mM L-
arginine (Santa Cruz Biotechology), high glucose cultured D407
cells were collected to isolate total RNA using the Trizol RNA
extraction reagent (Invitrogen, Guangzhou, China) according to
the manufacturer’s instructions. Purified RNA was reverse-
transcribed using a SYBR PrimeScriptTM RT–PCR Kit
(TaKaRa Corp, Dalian, China). Real-time quantification of
human MDR1, iNOS, and pregnane X receptor (PXR) mRNA
were performed on an ABI PRISM 7000 Sequence Detection
System using SYBR Green I as the reporter dye (TaKaRa Corp).
The comparative Ct method was employed while the relative
quantity of the target gene mRNA, normalized to GAPDH and
relative to the calibrator, was expressed as fold change=2
2DDCt.
The primers used for amplification were from different exons and
their sequences were as follows: MDR1, 59-TGGCACCCAGCA-
CAATGAA-39 and 59-CTAAGTCATAGTCCGCCTAGAAG-
CA-39; iNOS, 59- GACTTCTGTGACCTCCA -39 and 59-
GGTGATGCTCCCAGACAT -39; PXR, 59-GGCCACTGGC-
TATCACTTCAA-39 and 59-GTTTCATGGCCCTCCTGAAA-
39; GAPDH, 59-GCA CCG TCA AGG CTG AGA AC-39and 59-
TGG TGA AGA CGC CAG TGG A-39. Duplicate PCR
reactions were tested using the following amplification protocol:
95uC for 10 s followed by 30 cycles at 95uC for 5 s and at 60uC for
31 s.
Western blot analysis
Proteins were separated using 12% SDS-polyacrylamide gels.
The resolved proteins were transferred electrically to PVDF
membranes and incubated with 5% skim milk in TBS with 0.05%
Tween-20. The membranes were probed with primary antibodies
for P-gp (C219, Calbiochem, CA, USA) and iNOS (iNOS
antibody, Cell Signaling Technology, Shanghai, China) in
blocking buffer overnight at 4uC. They were then incubated with
horseradish peroxidase (HRP)-conjugated anti-mouse and anti-
rabbit secondary antibodies (Santa Cruz Biotechnology) for 1 h at
room temperature. As an internal control, the levels of ACTB (b-
actin) were examined at the same time. After washing, the
immunoreactive bands were detected using ECL chemilumines-
cence reagents. For P-gp expression, mouse fibroblast cell line
NIH/3T3 (ATCC, CRL-1658) known for expressing low/no P-gp
was used as a negative control [24]; and MDR cell line KB-V1
(Center of Experimental Animal, Sun Yat-sen University,
Guangzhou, China), which expresses high levels of P-gp [25],
was included as a positive control. The density of the bands was
quantified using a laser densitometer (ATTO densitograph 4.0,
Fujifilm, Tokyo, Japan). Each experiment was repeated at least
three times.
Rhodamine 123 accumulation assay
P-glycoprotein function was determined by rhodamine 123
(Invitrogen, Guangzhou, China) accumulation assay. Rhodamine
123, a fluorescent substrate for efflux transporters, has been used
as a marker to study the function of P-gp in various MDR cells and
various normal tissues including the human outer BRB [15,23,26].
Fluorescence intensity of intracellular rhodamine 123 was
determined by flow cytometry. D407 cells were cultured in six-
well plates at a density of 5610
5 cells/well and were loaded with
rhodamine 123 (10 mg/mL) for 1 h at 37uC in the dark. After 1 h
incubation, cells were washed and fed with rhodamine 123-free
culture medium. To exclude dead cells, cells were then stained
with 5 mg/mL propidium iodide (PI), a non-permeant dye that
cannot stain living cells for 10 min. Cells were trypsinized, washed
twice with cold PBS, resuspended in 200 ml PBS, and analyzed
immediately by flow cytometry analysis using a BD FACS AriaTM
flow cytometer and BD FACSDiVa software (Becton Dickinson,
CA, USA). Photomultiplier settings were adjusted to detect green
fluorescence of rhodamine 123 on the filter detector at an
excitation wavelength of 488 nm and emission wavelength of
525 nm, and detect red fluorescence of PI at an emission
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were analyzed. All experiments used six wells per condition and
were repeated on two to three separate occasions. The mean
fluorescence intensity in arbitrary units was used for data
presentation.
To check the integrity of the RPE monolayer, the transepithelial
electrical resistance (TEER), expressed as VNcm
2, was measured
with an epithelial voltmeter (MILLICELLERS; Millipore, Bill-
erica, MA, USA) at the end of the rhodamine 123 accumulation
experiments.
Statistical analysis
All data were expressed as mean 6 standard error (SE).
Statistical significance was determined using Student’s t-test (two-
tailed) or one way ANOV followed by appreciated multiple post
hoc testing. A probability (P) value of less than 0.05 was considered
statistically significant.
Results
Decreased expression of P-gp at both mRNA and protein
levels in the high glucose cultured RPE cells
To examine the changes of P-gp expression across time at the
outer BRB under hyperglycemic conditions, we first examined the
MDR1 mRNA level in the RPE cells incubated for 6–144 h in
intermediate (12.5 mM) or high glucose (25 or 50 mM). The
incubation with 5.5 mM normal glucose was used as control. As
show in Figure 1A, exposure to high, but not intermediate, glucose
induced a significant decrease in MDR1 mRNA level by 24 h,
when compared with normal control. This decrease did not
recover to the normal level after 144 h incubation with high
glucose. However, 50 mM glucose injured proliferation of the
RPE cells after 48 h incubation (Figure 1B). Thus, RPE cells were
exposed to 25 mM glucose in the subsequent experiments to
manifest the high glucose effects. Consistently, the protein level of
P-gp determined by western blot analysis was also decreased with
high glucose treatment for 24–144 h (Figure 1C). This correlated
well with the MDR1 mRNA level. In view of this, subsequent
studies were performed majorly with 25 mM glucose incubation
for 24 h. The down-regulation of P-gp was also observed following
long-term (14 days) exposure to high glucose (Figure 1C, lane 7), a
situation that mimics better the chronic hyperglycemia of diabetes.
Elevated expression and activity of iNOS in the high
glucose cultured RPE cells
Accumulated evidences have demonstrated that hyperglycemia
induces iNOS gene expression and nitrosative stress [27,28,29].
To verify the role of iNOS induction at the outer BRB under
hyperglycemic conditions, we firstly set to examine the iNOS
expression by Q-PCR and western blot. As shown in Figure 2,
high glucose induced significant increase in the expression at both
the mRNA and protein levels after incubation for 24 h. It is known
that iNOS produces large amounts of NO as a defense mechanism
in various tissue. Then we assessed iNOS activity by measuring
extracellular nitrate/nitrite concentrations as an indirect measure
of iNOS-mediated intracellular NO production. In consistent with
the upregulation in iNOS expression, cell supernatant nitrate/
nitrite increased markedly by 6 h when compared with normal
glucose medium, and reached a peak by 24 h after high glucose
incubation (Figure 3). These findings indicate that high glucose
activates the iNOS/NO induction in the cultured human RPE
cells.
Decreased P-gp expression at both mRNA and protein
levels by high glucose involves iNOS
One technique commonly used to investigate the role of iNOS
induction is administration of selective iNOS inhibitor such as
PBITU. We first set a pilot study to determine the concentration of
PBITU which abolished NO production by iNOS and found that
the high glucose-stimulated NO production after 12 h was
successfully blocked by 1 h preincubation of the RPE cells with
0.4 or 0.8 mM PBITU (Figure 3). Thus subsequent PBITU
Figure 1. Expression changes of MDR1 gene and p-glycopro-
tein by exposure of high glucose. (A) D407 cells were incubated for
6–144 h in intermediate (12.5 mM) or high glucose (25 or 50 mM)
medium and then MDR1 mRNA levels were assessed by quantitative
real-time polymerase chain reaction. Results are normalized to control
cells. Cells cultured in normal glucose were used as control. Data are
means 6 SE of four independent experiments.
*P,0.05, **P,0.01 vs the
normal controls. (B) RPE cells were exposed to 5.5, 12.5, 25, or 50 mM
glucose for 6–144 h and then cell proliferation by Thiazolyl blue
tetrazolium bromide (MTT) assay was determined.
*P,0.05, **P,0.01 vs
the controls. (C) D407 cells were treated with 25 mM for designed time
periods. The expression of p-glycoprotein and ACTB were determined
by western blots. ACTB was used as loading control. Mouse fibroblast
NIH/3T3 cells and multidrug resistant human cervix carcinoma KB-V1
cells served as negative and positive controls, respectively. The data
represent a western blot analysis from an individual experiment
performed at least 3 times. P-gp, p-glycoprotein; Negat, negative
control; Posit, positive control.
doi:10.1371/journal.pone.0031631.g001
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Then we set to determine whether iNOS was involved in the high
glucose-decreased P-gp expression or not. As shown in Figure 4,
the PBITU pretreatment significantly ameliorated the high
glucose-decreased P-gp expression at the mRNA (Figure 4A,
compare bars 2 and 3) and protein levels (Figure 4B, compare
lanes 2 and 3).
Although the above results showed that high glucose stimulated
iNOS induction and subsequent NO production (Figure 2 and 3),
it was unclear whether NO could affect the P-gp expression. To
test this, we next examined the effect of the NO donor, L-arginine,
on P-gp alteration by high glucose. As shown in Figure 4,
pretreatment with the addition of 1.0 mM L-arginine blocked the
effects of PBITU on the P-gp expression at mRNA levels
(Figure 4A, compare bars 3 and 4) and at protein levels
(Figure 4B, compare lanes 3 and 4) in high glucose cultured
D407 cells.
Decreased P-gp activity by high glucose involves iNOS
To assess the functional capacity of P-gp, cells were incubated
with rhodamine 123 and intracellular rhodamine 123 concentra-
tion was measured by flow cytometry analysis. As shown in
Figure 5, intracellular rhodamine 123 of D407 cells cultured in
high glucose was significantly increased when compared with
normal glucose controls, indicative of decreased P-gp function. C4,
a cell-permeable cinnamoyl compound that reversibly inhibits P-
gp efflux function with no noticeable effect on P-gp expression
[30,31], further augmented the high glucose-mediated intracellu-
lar accumulation of rhodamine 123. The high glucose-mediated
intracellular accumulation of rhodamine 123 was reversed by the
pretreatment with PBITU 0.4 mM for 1 h. These effects of
PBITU were antagonized with the addition of 1.0 mM L-arginine.
Collectively, these results suggest that functional expression of P-gp
in the RPE cells under hyperglycemia involves iNOS induction.
Expression of the nuclear receptors PXR mRNA by high
glucose
Recent studies have revealed that PXR can function as a master
regulator to control the expression of phase I and phase II drug-
metabolizing enzymes, as well as members of the drug transporter
family, including MDR1 [21,32]. To further elucidate the iNOS
pathway in cultured RPE cells after exposure of high glucose, we
next assessed the expression level of this nuclear receptor. As
shown in Figure 6, Q-PCR revealed that the expression of PXR
after high glucose incubation was lower than basal level. However,
the pretreatment of PBITU partially blocked the downregulation
of PXR mRNA by high glucose. Furthermore, the PBITU
blockade was antagonized with the addition of L-arginine. These
results suggest that downregulation of PXR by high glucose is
mediated at least partially through the iNOS induction.
Discussion
The retinal pigment epithelium plays a central role in retinal
physiology by forming the outer BRB and supporting the function
of the photoreceptors. Alterations of this barrier have been
associated with various sight-affecting conditions, including DR
[6,8,30]. New therapeutic strategies addressed to modulate RPE
impairment are therefore warranted. Recently, changes of P-gp, a
well-known efflux pump, have been implicated in the pathogenesis
of many tissues under diabetic conditions [16,17,18,19,20]. In the
present study, we first asked whether the P-gp at the human outer
Figure 2. Expression levels of mRNA and protein of iNOS in the high glucose cultured human RPE cells. (A) Expression iNOS mRNA in
D407 cells was determined by real-time polymerase chain reaction. The change in gene expression is expressed as fold change in relation to the
control. Data are means 6 SE of four independent experiments. **P,0.01 compared with cells incubated in the control. (B) Western blot analysis
using monoclonal antibodies against iNOS and ACTB. The data represent a western blot analysis from an individual experiment performed at least 3
times. NG, normal glucose; HG, high glucose; iNOS, inducible nitrate oxide synthase.
doi:10.1371/journal.pone.0031631.g002
Figure 3. Indirect nitric oxide production by D407 cells
following high glucose and iNOS inhibitor incubation. After
1 h preincubation with different concentrations of iNOS inhibitor PBITU,
cells were cultured in high glucose for 0–48 h. Nitric oxide production
was assessed by measuring extracellular nitrate/nitrite concentrations in
culture supernatants using Griess reaction. Data are means 6 SE of four
independent experiments. *P,0.05, **P,0.01 compared with cells
incubated in control;
#P,0.05,
##P,0.01 compared with cells
incubated in high glucose. NG, nomal glucose; HG, high glucose;
HG+PBITU 0.2, high glucose group pretreated with PBITU 0.2 mM;
HG+PBITU 0.4, high glucose group pretreated with PBITU 0.4 mM;
HG+PBITU 0.8, high glucose group pretreated with PBITU 0.8 mM.
doi:10.1371/journal.pone.0031631.g003
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that iNOS activity is induced in DR [27,28,29], and that NO is a
crucial regulatory mediator for functional expression of the barrier
transporters [33,34,35]. Thus, whether the iNOS induction was
involved in the regulation of P-gp at the outer BRB or not would
be our next question.
Our first key finding demonstrated that the basal levels of
transcriptional, translational, and functional P-gp in cultured
human RPE cells could be inhibited under hyperglycemic
conditions. This finding has important clinical implications.
According to the documented studies, a function of P-gp to RPE
is to limit the accumulation of toxic drugs or metabolites from the
subretinal space and thus serves a protective role for the neural
retina. Inhibition of P-gp by high glucose will potentially decrease
the normal transport function of the RPE. Another characteristic
of P-gp is to expel a broad range of hydrophobic compounds
including certain hydrophobic drugs widely used in clinical
therapy, such as steroids. From this view, we can also postulate
that decreased P-gp expression at the outer BRB may increase the
penetration of therapeutic agents targeted to specific areas of the
retinal neuron. Mechanisms responsible for altered P-gp in this
study have not been extensively investigated, but subsequent
deterioration of the outer BRB and alteration of pharmacokinetics
of therapeutic drugs are certainly possibilities. They imply
increased difficulties in protection against neurotoxicants and
alterations in pharmacokinetics of therapeutic drugs targeted to
the retinopathies.
Since diabetes is known to produce a nitrosative stress condition
and the exposure of NO may lead to a regulation of the gene
expression of efflux transporters [34,35], the role of NO in the
functional alterations of P-gp at the BRB was of particular interest.
Here we found that the decreased expression and activity of P-gp
was associated with an iNOS induction and subsequent NO
production in the high glucose cultured RPE cells. Moreover, the
pretreatment with PBITU partially blocked the decreased func-
tional expression of P-gp. The addition of L-arginine antagonized
the blockade effects of PBITU. It is because that PBITU competes
with L-arginine for the binding site on iNOS [36]. Hence,
pretreatment with PBITU only partially blocked iNOS activity
and subsequent NO production. Our finding is consistent with
previousinvestigationinexperimentaldiabetesthat iNOS induction
is involved in the reduction of ileal P-gp expression. However, it
does not agree with the finding from Maeng and colleagues [17].
They reported that nitrosative stress leads to up-regulation of P-gp
at the blood-brain barrier of diabetic rats. The possible explanation
for this discrepancy is that P-gp in different tissue barriers may have
tissue-specific characteristic responses to the nitrosative stress, such
as diabetes. Indeed, in another nitrosative stress model using
lipopolysaccharide treatment, it has been demonstrated that
expression and/or function of ABC transporters (i.e., P-gp) were
differentially regulated in a tissue-specific manner. Namely,
lipopolysaccharide-induced acute inflammation caused down-
regulation of P-gp in the brain, the intestine, and the liver, but
up-regulationof P-gp in the kidney[34,37,38,39].Since the findings
from others and ours indicate the existence of functional efflux
transportersincludingP-gpindifferenttissuebarriersunderdiabetic
conditions, a cell or tissue-specific regulatory mechanism of
nitrosative stress may exist in the case of P-gp.
Nitric oxide is produced by different isoforms of NOS. In the
retina, constitutive NOS and iNOS are present, the former in
amacrine and ganglion cells and the latter in RPE and Mu ¨ller cells
[40,41]. RPE cells from bovine [42], human [43], and murine [40]
species have been identified containing the iNOS isoform. RPE
cells have also been shown to produce NO in response to a
number of cytokines [43], and it has been suggested that RPE-
derived NO may be involved in the maintenance of barrier
integrity and function [42,44]. The present study suggests that
iNOS/NO signaling pathway also has a role in the regulation of
transporter functions at the human outer BRB. How the iNOS
pathway and P-gp interact or coordinate at the outer BRB to the
response to hyperglycemia is uncertain. However, it is possible that
there is both some redundancy in the response, as well as cell and
tissue-specific aspects to iNOS mediation. In the context of the
present study, it is worth pointing out that iNOS has been added
to the list of therapeutic targets for the DR. The upregulation of
iNOS has been reported in retinas of experimental diabetic
rodents and patients in most studies [27,28,29]. Recently, Zheng
et al. [45] has demonstrated directly that the critic role of iNOS in
Figure 4. Decreased p-glycoprotein expression by high glucose
involves iNOS. (A) Cells incubated in high glucose were pretreated
with iNOS inhibitor PBITU (0.4 mM) alone or combined with nitric oxide
donor L-arginine (1.0 mM) for 1 h. Expression of MDR1 mRNA in D407
cells was determined by quantitative real-time polymerase chain
reaction. The change in gene expression is expressed as fold change
in relation to the control. Data are means 6 SE of four independent
experiments. **P,0.01 compared with cells incubated in normal
glucose medium;
#P,0.05 compared with cells incubated in high
glucose;
$P,0.05 compared with cells incubated in high glucose and
PBITU. (B) Western blot analysis using monoclonal antibodies against p-
glycoprotein and ACTB. The expression of ACTB was used as a control.
The data represent a western blot analysis from an individual
experiment performed at least 3 times. P-gp, p-glycoprotein.
doi:10.1371/journal.pone.0031631.g004
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Aminoguanidine, a relatively selective inhibitor of iNOS [46], has
been found to inhibit the diabetes-induced iNOS expression and
NO production in retina [47], and to subsequently inhibit the
development of the DR [48]. Our finding of the restored
functional expression of P-gp suggests that iNOS inhibitor has a
beneficial effect on the integrity of the outer BRB under
hyperglycemic conditions, and further supports the concept of
inhibiting iNOS pathway as a therapeutic strategy for DR.
There are a number of transacting factors which are essential
for the activation of human MDR1 gene at transcriptional level.
Among them are expression and regulation of transcriptional
factors such as Y-box binding-1 [49], Hypoxia-inducible factor 1
and PXR (also known as SXR in human) [35]. PXR is a member
of a superfamily of ligand-activated transcription factors, the so-
called orphan nuclear receptors. In hepatocytes, ligand-activated,
nuclear receptors are transcriptional regulators of drug metabo-
lizing enzymes and drug export pumps, but only one, the PXR,
Figure 5. Decreased P-gp functional activity by high glucose involves iNOS. (A) P-gp function was determined by intracellular rhodamine
123 accumulation by flow cytometry. D407 cells were incubated in normal (a) and high glucose medium (b–e), respectively. Cells incubated in high
glucose were pretreated with C-4 (c), or PBITU alone (d) or combined with L-arginine (e) for 1 h. Following the treatment, cells were then loaded with
a rhodamine 123 (10 mg/mL). The mean fluorescence intensity of intracellular rhodamine 123 was determined by flow cytometry. The results shown
are representative of those for three separate experiments. (B) The bar represents the mean 6 SE for the three separate experiments. *P,0.05 and
**P,0.01 compared with cells incubated in normal glucose medium;
#P,0.05 compared with cells incubated in high glucose;
$P,0.05 compared
with cells incubated in high glucose and C4;
DP,0.05 compared with cells incubated in high glucose and PBITU. HG, high glucose.
doi:10.1371/journal.pone.0031631.g005
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mRNA levels of PXR, which were consistent with the attenuated
expression of P-gp after incubation with high glucose (see Figure 1
and 6), indicate that PXR is a potential therapeutic target at the
transcriptional level for the transport function at BRB under
hyperglycemic conditions. To the best of our knowledge, this is the
first evidence for PXR expression in the human RPE cells and for
possible regulation by nuclear receptors of xenobiotic efflux pumps
at the outer BRB. We then assumed that NO might be able to
suppress PXR, leading to an inhibition of MDR1 and other PXR
target genes. Although a previous report indicated that the
promoter of iNOS contained a PXR-responsive element, and that
increased expression of iNOS was a direct response to PXR
activation [50], our results suggest that it is the iNOS induction
which mediates PXR-associated events in the RPE cells.
Consistent with this view is the finding from Mitchell et al. study
that iNOS mediates contractility through PXR in uterine tissues
[51]. Mechanisms responsible for this have not been identified, but
tonic regulation of PXR by iNOS or by endogenous ligands
produced under hyperglycemic conditions are certainly possibil-
ities. In fact, PXR, other nuclear receptors, e.g., CAR, xenobiotic
metabolizing enzymes, and efflux transporters have been demon-
strated to comprise a regulated network of core defense
mechanisms in the liver [52,53]. Further investigation into the
role of cell signaling pathways in iNOS-mediated transcription,
and into signaling pathway crosstalk will be necessary to fully
understand the functional implication of these signaling events at
the human outer BRB.
In conclusion, our results provide clear evidence that iNOS
induction participates the decreased expression and activity of P-
gp by high glucose in the cultured human RPE cells, and indicate
that iNOS signaling pathway has a novel role in the regulation of
transporter expressions and functions at the human outer BRB.
Taken in the context of previous studies demonstrating a role of
iNOS activity, the concept of inhibiting iNOS pathway as a
therapeutic strategy deserves further evaluation for the prevention
of DR.
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